Keymed Biosciences (HKSE:02162) FCF Margin % : -1,580.17% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Keymed Biosciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Keymed Biosciences's Free Cash Flow for the six months ended in Dec. 2023 was HK$-466.1 Mil. Keymed Biosciences's Revenue for the six months ended in Dec. 2023 was HK$29.5 Mil. Therefore, Keymed Biosciences's FCF Margin % for the quarter that ended in Dec. 2023 was -1,580.17%.

As of today, Keymed Biosciences's current FCF Yield % is -6.89%.

The historical rank and industry rank for Keymed Biosciences's FCF Margin % or its related term are showing as below:

HKSE:02162' s FCF Margin % Range Over the Past 10 Years
Min: -681.05 Med: -351.41 Max: -193.8
Current: -193.8

During the past 5 years, the highest FCF Margin % of Keymed Biosciences was -193.80%. The lowest was -681.05%. And the median was -351.41%.

HKSE:02162's FCF Margin % is ranked worse than
53.64% of 1044 companies
in the Biotechnology industry
Industry Median: -146.375 vs HKSE:02162: -193.80

Keymed Biosciences FCF Margin % Historical Data

The historical data trend for Keymed Biosciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keymed Biosciences FCF Margin % Chart

Keymed Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-351.41

-681.05

-193.80

Keymed Biosciences Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial				-260.84	-352.71	-524,494.29	-79.50	-1,580.17

Competitive Comparison of Keymed Biosciences's FCF Margin %

For the Biotechnology subindustry, Keymed Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Keymed Biosciences's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keymed Biosciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Keymed Biosciences's FCF Margin % falls into.

Keymed Biosciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Keymed Biosciences's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-750.584	/	387.302
	=	-193.80 %

Keymed Biosciences's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-466.149	/	29.5
	=	-1,580.17 %

Keymed Biosciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Keymed Biosciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Keymed Biosciences (HKSE:02162) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keymed Biosciences Inc (HKSE:02162) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

64Z:Germany

Address

No. 18 BioTown Middle Road, Building D2, Tianfu International BioTown, Chengdu, Sichuan, CHN, 610219

Website

https://www.keymedbio.com

Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of innovative biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it operates in Hong Kong & Mainland China, out of which the majority is from Mainland China.

Keymed Biosciences (HKSE:02162) Headlines

No Headlines